AbbVie (NYSE:ABBV) Shares Down 1.5% – Time to Sell?

Posted by Brenda Bartman on Sep 4th, 2026

AbbVie Inc. (NYSE:ABBV – Get Free Report) fell 1.5% on Friday . The stock traded as low as $255.58 and last traded at $256.27. Approximately 4,679,176 shares changed hands during trading, a decline of 30% from the average session volume of 6,685,035 shares. The stock had previously closed at $260.21.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Etentamig delivers a major pipeline win: AbbVie’s investigational BCMA×CD3 bispecific T-cell engager met both primary endpoints in the Phase 3 CERVINO trial for relapsed or refractory multiple myeloma. The drug produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60% (hazard ratio 0.40). The results could support regulatory filing and position etentamig to compete in the growing multiple-myeloma market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
Positive Sentiment: Apogee acquisition expands immunology exposure: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics, adding late-stage IL-13 antibody zumilokibart for atopic dermatitis and additional asthma programs. The deal strengthens AbbVie’s post-Humira growth pipeline, although management expects near-term earnings dilution before the transaction becomes accretive, reportedly in 2032. AbbVie Completes Acquisition of Apogee Therapeutics
Neutral Sentiment: Guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The full-year range is broadly in line with the approximately $14.02 analyst consensus, offering little new upside or downside surprise.
Negative Sentiment: Humira erosion remains a key overhang: Humira revenue continues to fall as biosimilar competition intensifies, raising questions about how long AbbVie can sustain dividend growth and replace the former blockbuster’s cash flow. Growth from Skyrizi and Rinvoq helps offset the decline, but investors remain focused on execution and the company’s elevated valuation. AbbVie’s Humira Cash Cow Is Shrinking

Analysts Set New Price Targets

Several research analysts have commented on ABBV shares. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Finally, Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.

View Our Latest Report on AbbVie

AbbVie Stock Performance

The company has a market cap of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The business’s fifty day moving average is $254.57 and its two-hundred day moving average is $229.87.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period last year, the company posted $2.97 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several large investors have recently modified their holdings of the business. ACT Advisors LLC. raised its position in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC lifted its position in shares of AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its holdings in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after buying an additional 43 shares in the last quarter. Fielder Capital Group LLC grew its position in shares of AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its stake in shares of AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after acquiring an additional 43 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.